----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      10-QSB**

| x                                                                                                                                                                                                                                                                      |   | Quarterly                Report pursuant to Section 13 or 15(d) of the Securities Exchange                Act of                1934 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                   |   |                                                                                                                                 |
| For                the                quarterly period ended June 30, 2007                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                   |   |                                                                                                                                 |
| **o**                                                                                                                                                                                                                                                                  |   | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934                |
|                                                                                                                                                                                                                                                                   |   |                                                                                                                                 |
| For                the                transition period from                                                            to |

**Commission      File No. 333-123431**

**PATHOGENICS,      INC.**

| **Delaware**                                                                                                                                                                                     |   | ** 2833**                                                          |   | **43-2078278**                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------|--------|------------------------------------------------------------------|
| (State                or                Other Jurisdiction of Incorporation)                                                                                                                     |   | (Primary                Standard Industrial Classification Code Number) |   | (IRS                Employer                Identification. No.) |
|                                                                                                                                                                                             |   |                                                                    |   |                                                             |
| 99                Derby                Street, Suite 200, Hingham, MA 02043                                                                                                                      |
| (Address                of                Principal Executive Offices) (Zip Code)                                                                                                                |
|                                                                                                                                                                                             |
| Issuer’s                telephone number, including area code: (781) 556-1090                                                                                                              |
|                                                                                                                                                                                             |   |                                                                    |   |                                                             |
| Securities                registered pursuant to  Section 12(b) of the Exchange                Act:     None                                             |
|                                                                                                                                                                                             |
| Securities                registered pursuant to Section 12(g) of the                Act:     Common Stock, par value $0.001 per                share    |

----

----

**PART      I –FINANCIAL INFORMATION**

**PATHOGENICS,      INC.**

**CONSOLIDATEDBALANCE      SHEETS**

**As      of June 30,2007      and December 31, 2006**

**(Unaudited)**

|                                                                                                                                                            |   | **June 30,****2007** |     |   | **December 31,****2006** |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------|----------|--------|-------------------------------|--------|
| ASSETS                                                                                                                                                          |   |                      |     |   |                          |   |
| Current                Assets                                                                                                                                   |   |                      |     |   |                          |   |
| Cash                                                                                                                                                            |   | $                         | 10,512   |   |                          | $      | 86,686 |   |
| Accounts                receivable                                                                                                                              |   |                      | 30,890   |   |                          |   | – |   |
| Note                receivable                                                                                                                                  |   |                      | 140,705  |   |                          |   | 140,705 |   |
| Interest                receivable                                                                                                                              |   |                      | 8,208    |   |                          |   | 1,173 |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
| TOTAL                ASSETS                                                                                                                                     |   | $                         | 190,315  |   |                          | $      | 228,564 |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
| LIABILITIES                AND SHAREHOLDERS’ DEFICIT                                                                                                      |   |                      |     |   |                          |   |   |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
| LIABILITIES                                                                                                                                                     |   |                      |     |   |                          |   |   |   |
| Current                Liabilities                                                                                                                              |   |                      |     |   |                          |   |   |   |
| Accounts                payable and accrued liabilities                                                                                                         |   | $                         | 618,187  |   |                          | $      | 530,230 |   |
| Advances                from                Egenix                                                                                                              |   |                      | –  |   |                          |   | 85,545 |   |
| Loans                payable                – related parties                                                                                             |   |                      | –  |   |                          |   | 23,921 |   |
| TOTAL                LIABILITIES                                                                                                                                |   |                      | 618,187  |   |                          |   | 639,696 |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
| Shareholders’                Deficit                                                                                                                      |   |                      |     |   |                          |   |   |   |
| Preferred                stock, $0.001 par value, 10,000,000 shares authorized, none issued                and                outstanding                       |   |                      | –  |   |                          |   | – |   |
| Common                stock,                $0.001 par value, 100,000,000 shares  authorized, 50,257,270                shares issued and outstanding |   |                      | 50,257   |   |                          |   | 50,257 |   |
| Additional                paid-in capital                                                                                                                       |   |                      | 278,192  |   |                          |   | 278,192 |   |
| Accumulated                deficit                                                                                                                              |   |                      | (736,321 | )      |                          |   | (719,581 | ) |
| Treasury                stock, 689,655 shares                                                                                                                   |   |                      | (20,000  | )      |                          |   | (20,000 | ) |
| Total                shareholders’ deficit                                                                                                                |   |                      | (427,872 | )      |                          |   | (411,132 | ) |
|                                                                                                                                                            |   |                      |     |   |                          |   |   |   |
| TOTAL                LIABILITIES AND SHAREHOLDERS’ DEFICIT                                                                                                |   | $                         | 190,315  |   |                          | $      | 228,564 |   |

----

**PATHOGENICS,      INC.**

**CONSOLIDATEDSTATEMENTS      OF      EXPENSES**

**ThreeMonthsand      Six Months EndedJune      30, 2007      and 2006**

**(Unaudited)**

|                                                                                |   | Three                Months                Ended June 30, |       |   | Six                Months                Ended June 30, |   |
|-------------------------------------------------------------------------------------|--------|-----------------------------------------------------------|------------|--------|---------------------------------------------------------|--------|
|                                                                                |   | 2007                                                      |       |   | 2006                                                    |   |   | 2007 |   |   | 2006 |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |
| Revenue–                license fees                                          |   | $                                                         | –    |   |                                                    | $      | 50,000 |   |   | $ | – |   |   | $ | 50,000 |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Operating                Expenses:                                                  |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| General                and                administrative                            |   |                                                      | 121,681    |   |                                                    |   | 74,703 |   |   |   | 240,626 |   |   |   | 128,402 |   |
| Research                and                development                              |   |                                                      | 54,831     |   |                                                    |   | 47,595 |   |   |   | 107,713 |   |   |   | 77,155 |   |
| Total                Operating Expenses                                             |   |                                                      | 176,512    |   |                                                    |   | 122,298 |   |   |   | 348,339 |   |   |   | 205,557 |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Operating                loss                                                       |   |                                                      | (176,512   | )      |                                                    |   | (72,298 | ) |   |   | (348,339 | ) |   |   | (155,557 | ) |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Other                Income                (Expense):                               |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Interest                income                                                      |   |                                                      | 3,519      |   |                                                    |   | – |   |   |   | 7,035 |   |   |   | – |   |
| Interest                expense                                                     |   |                                                      | (6,529     | )      |                                                    |   | (7,487 | ) |   |   | (15,981 | ) |   |   | (15,533 | ) |
| Gain                on                forgiveness of debt                           |   |                                                      | 340,545    |   |                                                    |   | – |   |   |   | 340,545 |   |   |   | – |   |
| Total                Other                Income (Expense)                          |   |                                                      | 337,535    |   |                                                    |   | (7,487 | ) |   |   | 331,599 |   |   |   | (15,533 | ) |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Net                income                (loss)                                     |   |                                                      | 161,023    |   |                                                    |   | (79,785 | ) |   |   | (16,740 | ) |   |   | (171,090 | ) |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Preferred                dividends                                                  |   |                                                      | –    |   |                                                    |   | – |   |   |   | – |   |   |   | – |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Net                income                (loss) attributable to common stockholders |   | $                                                         | 161,023    |   |                                                    | $      | (79,785 | ) |   | $ | (16,740 | ) |   | $ | (171,090 | ) |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Basic                and                diluted net loss per common share           |   | $                                                         | 0.00       |   |                                                    | $      | (0.00 | ) |   | $ | (0.00 | ) |   | $ | (0.00 | ) |
|                                                                                |   |                                                      |       |   |                                                    |   |   |   |   |   |   |   |   |   |   |   |
| Weighted                average common shares outstanding                           |   |                                                      | 49,567,615 |   |                                                    |   | 46,977,960 |   |   |   | 49,567,615 |   |   |   | 46,947,554 |   |

----

**PATHOGENICS,      INC.**

**CONSOLIDATED      STATEMENTS OF CASH      FLOWS**

**Six      Months Ended June      30, 2007      and 2006**

**(Unaudited)**

|                                                                                                                    |   | 2007   |     |   | 2006   |   |
|-------------------------------------------------------------------------------------------------------------------------|--------|--------|----------|--------|--------|--------|
|                                                                                                                    |   |   |     |   |   |   |
| CASH                FLOWS                FROM OPERATING ACTIVITIES                                                      |   |   |     |   |   |   |
| Net                loss                                                                                                 |   | $      | (16,740  | )      |   | $      | (171,090 | ) |
| Adjustments                to                reconcile net loss to cash used in operating activities:                   |   |   |     |   |   |   |   |   |
| Gain                on                forgiveness of debt                                                               |   |   | (340,545 | )      |   |   | – |   |
| Changes                in:                                                                                              |   |   |     |   |   |   |   |   |
| Accounts                receivable                                                                                      |   |   | (30,890  | )      |   |   | – |   |
| Interest                receivable                                                                                      |   |   | (7,035   | )      |   |   | – |   |
| Accounts                payable and accrued                liabilities                                                  |   |   | 87,957   |   |   |   | 145,084 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| Net                Cash Used                In Operating Activities                                                     |   |   | (307,253 | )      |   |   | (26,006 | ) |
|                                                                                                                    |   |   |     |   |   |   |   |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| CASH                FLOWS                FROM FINANCING ACTIVITIES                                                      |   |   |     |   |   |   |   |   |
| Advances                from                related parties                                                             |   |   | –  |   |   |   | 5,586 |   |
| Repayments                of                advances from related parties                                               |   |   | (23,921  | )      |   |   | (15,600 | ) |
| Advances                from                Egenix                                                                      |   |   | 255,000  |   |   |   | 53,480 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| Net                Cash                Provided By Financing Activities                                                 |   |   | 231,079  |   |   |   | 43,466 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| NET                CHANGE IN                CASH                                                                        |   |   | (76,174  | )      |   |   | 17,460 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| CASH                AT                BEGINNING OF PERIOD                                                               |   |   | 86,686   |   |   |   | 284 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| CASH                AT END OF                PERIOD                                                                     |   | $      | 10,512   |   |   | $      | 17,744 |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| Supplemental                disclosures:                                                                                |   |   |     |   |   |   |   |   |
| Interest                paid                                                                                            |   | $      | –  |   |   | $      | – |   |
| Income                tax                paid                                                                           |   |   | –  |   |   |   | – |   |
|                                                                                                                    |   |   |     |   |   |   |   |   |
| Non-cash                investing and financing transactions:                                                           |   |   |     |   |   |   |   |   |
| Issuance                of                common shares for liabilities                                                 |   | $      | –  |   |   | $      | 6,650 |   |
| Issuance                of                common shares to First Coventry for collateral on note                payable |   |   | –  |   |   |   | 20,000 |   |

----

----

**ITEM      2.  MANAGEMENT’S      DISCUSSION AND ANALYSIS OF FINANCIAL      CONDITION AND RESULTS OF OPERATIONS.**

**You      should      read the following discussion of our results of operations and financial      condition in conjunction with our most recent Annual Report on Form 10-KSB      for      the year ended December 31, 2006. This discussion includes “forward-looking”statements that reflect our current views with respect to future events and      financial performance. We use words such as we “expect,” “anticipate,”“believe,” and “intend” and similar expressions to identify forward-looking      statements. Investors should be aware that actual results may differ materially      from our expressed expectations because of risks and uncertainties inherent      in      future events, particularly those risks identified in the “Risk Factors” section      of the Annual Report, and should not unduly rely on these forward looking      statements.**

**GENERAL**

----

----

**ITEM      3.  CONTROLS AND      PROCEDURES**

**PART      II**

**ITEM      1.  LEGAL      PROCEEDINGS**

**ITEM      2.  CHANGES IN      SECURITIES**

**ITEM      3.  DEFAULTS UPON SENIOR      SECURITIES**

**ITEM      4.  SUBMISSION OF MATTERS      TO A VOTE OF SECURITY HOLDERS**

**ITEM      5.  OTHER      INFORMATION**

----

**ITEM      6.  EXHIBITS**

*(a)*

*Exhibits*

----

----

**SIGNATURES**

| By | /s/                Frederic P. Zotos |
|----|--------------------------------------|
|   |  |
|--------|--|
|   | Frederic              P.              Zotos, President, CEO and Director |
|--------|--------------------------------------------------------------------------|

----